Rodolphe Barrangou

Ancilia Biosciences, Inc. is an American company that is developing virus-resistant live bacterial biotherapeutics to alter the gut microbiome and treat disease. Ancilia is based in the United States, and its founders and advisers include key scientific leaders across CRISPR and the virome. Ancilia's proprietary platform is being developed as an essential enabling technology that characterizes viral phages and leverages the natural function of CRISPR to produce a new class of live biotherapeutics with engineered immunity to key viral pathogens. The company has demonstrated proof of principle and filed key patents for the technology. The company was founded to overcome a potential obstacle to the success of LBPs, which is their failure to address the role of predatory viral phages in causing disease and limiting the ability of LBPs to engraft in the gut. The company was founded by Alexandra Sakatos, who has been the CEO since incorporation.

Ancilia Biosciences, Inc. is an American company that is developing virus-resistant live bacterial biotherapeutics to alter the gut microbiome and treat disease. Ancilia is based in the United States, and its founders and advisers include key scientific leaders across CRISPR and the virome. Ancilia's proprietary platform is being developed as an essential enabling technology that characterizes viral phages and leverages the natural function of CRISPR to produce a new class of live biotherapeutics with engineered immunity to key viral pathogens. The company has demonstrated proof of principle and filed key patents for the technology. The company was founded to overcome a potential obstacle to the success of LBPs, which is their failure to address the role of predatory viral phages in causing disease and limiting the ability of LBPs to engraft in the gut. The company was founded by Alexandra Sakatos, who has been the CEO since incorporation.